Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer.
Looking at options history for Pfizer (NYSE:PFE) we detected 18 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $635,420 and 15, calls, for a total amount of $588,190.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $31.0 for Pfizer, spanning the last three months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $25.0 to $31.0, over the past month.
Pfizer Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.69 | $0.61 | $0.66 | $25.00 | $327.5K | 58.9K | 5.0K |
PFE | PUT | TRADE | BULLISH | 06/07/24 | $0.19 | $0.18 | $0.18 | $28.00 | $241.9K | 1.6K | 14.4K |
PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.3 | $0.29 | $0.3 | $30.00 | $95.5K | 2.4K | 6.7K |
PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.66 | $0.62 | $0.66 | $25.00 | $66.0K | 58.9K | 7.0K |
PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.19 | $0.17 | $0.18 | $30.00 | $56.4K | 2.4K | 3.2K |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Pfizer's Current Market Status
With a trading volume of 17,877,955, the price of PFE is up by 2.47%, reaching $29.27.
Current RSI values indicate that the stock is may be overbought.
Next earnings report is scheduled for 69 days from now.
Expert Opinions on Pfizer
In the last month, 2 experts released ratings on this stock with an average target price of $32.5.
An analyst from BMO Capital has revised its rating downward to Outperform, adjusting the price target to $36.
Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Pfizer with a target price of $29.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
有大量資金可以花的大戶對輝瑞採取了明顯的看漲立場。
查看輝瑞(紐約證券交易所代碼:PFE)的期權歷史記錄,我們發現了18筆交易。
如果我們考慮每筆交易的具體情況,可以準確地說,55%的投資者以看漲的預期開倉,44%的投資者以看跌的預期開盤。
在已發現的全部交易中,有3筆是看跌期權,總額爲635,420美元,15筆是看漲期權,總額爲588,190美元。
預期的價格走勢
在評估了交易量和未平倉合約之後,很明顯,主要市場走勢者將注意力集中在輝瑞過去三個月的25.0美元至31.0美元之間的價格區間上。
對交易量和未平倉合約的見解
檢查交易量和未平倉合約爲股票研究提供了至關重要的見解。這些信息是衡量輝瑞期權在特定行使價下的流動性和利息水平的關鍵。下面,我們簡要介紹了過去一個月輝瑞重大交易的看漲期權和未平倉合約的趨勢,行使價區間爲25.0美元至31.0美元。
輝瑞看漲期權和看跌期權交易量:30天概述
值得注意的期權活動:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.69 | $0.61 | $0.66 | $25.00 | $327.5K | 58.9K | 5.0K |
PFE | PUT | TRADE | BULLISH | 06/07/24 | $0.19 | $0.18 | $0.18 | $28.00 | $241.9K | 1.6K | 14.4K |
PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.3 | $0.29 | $0.3 | $30.00 | $95.5K | 2.4K | 6.7K |
PFE | PUT | SWEEP | BEARISH | 01/17/25 | $0.66 | $0.62 | $0.66 | $25.00 | $66.0K | 58.9K | 7.0K |
PFE | CALL | SWEEP | BULLISH | 06/07/24 | $0.19 | $0.17 | $0.18 | $30.00 | $56.4K | 2.4K | 3.2K |
關於輝瑞
輝瑞是全球最大的製藥公司之一,年銷售額接近 500 億美元(不包括 COVID-19 產品的銷售額)。儘管它歷來銷售許多類型的醫療保健產品和化學品,但現在處方藥和疫苗佔銷售額的大部分。最暢銷的產品包括肺炎球菌疫苗Prevnar 13、抗癌藥物Ibrance和心血管治療藥物Eliquis。輝瑞在全球銷售這些產品,國際銷售額佔總銷售額的近50%。在國際銷售中,新興市場是主要貢獻者。
在我們分析了與輝瑞相關的期權活動之後,我們將着手仔細研究公司自身的業績。
輝瑞目前的市場地位
關於輝瑞的專家意見
上個月,2位專家發佈了該股的評級,平均目標價爲32.5美元。
交易期權涉及更大的風險,但也提供了更高利潤的潛力。精明的交易者通過持續的教育、戰略貿易調整、利用各種指標以及隨時關注市場動態來降低這些風險。使用Benzinga Pro了解輝瑞的最新期權交易,以獲取實時警報。